Summary:
TOBY, Inc. has completed its participation in the prestigious Mayo Clinic and Arizona State University MedTech Accelerator to advance its AI-powered, noninvasive urine test for early cancer detection.

Takeaways:

  1. Innovative Screening Tool: TOBY is developing a urine-based spectroscopy and AI platform to detect early-stage cancer through molecular pattern analysis.
  2. Prestigious Support: TOBY was one of ten global companies selected for the 2025 MedTech Accelerator, gaining access to expert mentorship and clinical resources.
  3. Rising Need: With cancer rates projected to increase, TOBY aims to make early detection more accessible and cost-effective, improving outcomes and reducing healthcare burdens.

TOBY, Inc., a biotechnology company focusing on improving early cancer screening, has announced its completion of its participation in the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator in Phoenix, AZ. Out of a global pool of applicants, only ten companies were selected for the 2025 cohort. 

TOBY Is Developing Noninvasive Urine Test for Early Cancer Detection

TOBY is developing a noninvasive urine spectroscopy and artificial intelligence (AI) platform for early cancer detection. The technology analyzes unique molecular signatures to support early, accessible, and cost-effective screening using a urine test. 

The Mayo Clinic and Arizona State University MedTech Accelerator supports early-stage medical technology companies through access to clinical, academic, and commercial resources. 

Participating companies receive mentorship and strategic guidance during the program and remain connected through the MedTech Accelerator network. 

“There is a critical need for screening methods that are accessible and affordable,” says Matthew Laskowski, chief executive officer of TOBY. “Participation in the MedTech Accelerator has been instrumental in advancing our technology and development strategy.” 

Cancer Incidence Projected to Rise Significantly

According to the International Agency for Research on Cancer (IARC), global cancer incidence is projected to rise significantly between 2022 and 2045. In the United States, the National Cancer Institute estimates that over 2 million people will be diagnosed with cancer in 2025. 

“Our goal is to support earlier detection, when treatment is most effective and the burden on patients and the healthcare system is reduced,” said Dragan Sebišanović, Chief Science Officer of TOBY. “Our technology uses machine learning to help identify molecular patterns associated with early-stage cancer.” 

Featured Image: Viktoriya Kuzmenkova | Dreamstime.com